CME Group (CME) Stock Forecast & Price Target

$248.88 +0.56 (+0.23%)

Closing price 02/21/2025 03:59 PM Eastern

Extended Trading

$248.78 -0.10 (-0.04%)

As of 02/21/2025 07:55 PM Eastern

CME Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 15 Analyst Ratings

Sell
4

Hold
8

Buy
3

Based on 15 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 15 analysts, 4 have given a sell rating, 8 have given a hold rating, and 3 have given a buy rating for CME.

Consensus Price Target

$236.13
-5.12% Downside

According to the 15 analysts' twelve-month price targets for CME Group, the average price target is $236.13. The highest price target for CME is $269.00, while the lowest price target for CME is $180.00. The average price target represents a forecasted downside of -5.12% from the current price of $248.88.

Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

CME Analyst Ratings Over Time

Type	Current Forecast 2/23/24 to 2/22/25	1 Month Ago 1/24/24 to 1/23/25	3 Months Ago 11/25/23 to 11/24/24	1 Year Ago 2/23/23 to 2/23/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	4 Buy rating(s)	3 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	7 Hold rating(s)	4 Hold rating(s)
Sell	4 Sell rating(s)	4 Sell rating(s)	4 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$236.13	$229.27	$224.47	$214.22
Forecasted Upside	-5.12% Downside	-1.76% Downside	-2.00% Downside	-1.71% Downside
Consensus Rating	Reduce	Reduce	Hold	Hold

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CME Group Stock vs. The Competition

Type	CME Group	Finance Companies	S&P 500
Consensus Rating Score	1.93	2.51	2.53
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	-5.12% Downside	26.61% Upside	14.38% Upside
News Sentiment Rating	Positive News See Recent CME News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/19/2025	Morgan Stanley 3 of 5 stars	Mike Cyprys Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$256.00 ➝ $263.00	+6.11%
2/14/2025	Keefe, Bruyette & Woods 4 of 5 stars	Kyle Voigt Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform ➝ Market Perform	$256.00 ➝ $257.00	+3.64%
2/13/2025	Oppenheimer 3 of 5 stars	Owen Lau Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$258.00 ➝ $269.00	+7.59%
2/13/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Sabadra Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$235.00 ➝ $269.00	+7.59%
2/13/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Kenneth Worthington Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Underweight ➝ Underweight	$209.00 ➝ $212.00	-15.54%
2/13/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Benjamin Budish Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$257.00 ➝ $263.00	+5.64%
1/7/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$250.00 ➝ $258.00	+14.25%
1/6/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Allen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$255.00 ➝ $250.00	+7.53%
11/11/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$227.00 ➝ $226.00	-0.14%
10/8/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Clinch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$244.00	+10.04%
Get the Latest News and Ratings for CME and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CME Group and its competitors with MarketBeat's FREE daily newsletter.
10/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sell ➝ Sell	$195.00 ➝ $198.00	-11.89%
10/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Underperform ➝ Underperform	$177.00 ➝ $180.00	-19.49%
9/26/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Katz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$221.00	+1.60%
4/25/2024	Rosenblatt Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Sell ➝ Sell	$185.00 ➝ $187.00	-12.04%
3/6/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$225.00 ➝ $245.00	+12.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 07:07 AM ET.

Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, February 16, 2025. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

Here are some ways that investors could benefit from investing in CME Group Inc.:

CME Group Inc. has a strong market capitalization of $88.46 billion, indicating a robust position in the financial services sector, which can provide stability and growth potential for investors.
The company reported a net margin of 57.34%, showcasing its efficiency in converting revenue into profit, which is a positive indicator for profitability and potential returns on investment.
With a recent stock price around $249.17, the company is engaging in a stock repurchase program worth $3.00 billion, suggesting that the board believes the stock is undervalued, which could lead to price appreciation.
CME Group Inc. has a low debt-to-equity ratio of 0.09, indicating a conservative approach to leverage, which reduces financial risk and enhances the company's ability to weather economic downturns.
The firm has a return on equity of 13.39%, reflecting effective management and the ability to generate profits from shareholders' investments, which is attractive for potential investors.

CME Group
Bear Case

Investors should be bearish about investing in CME Group Inc. for these reasons:

The price-to-earnings (P/E) ratio of 25.81 may indicate that the stock is overvalued compared to its earnings, which could deter value-focused investors.
With a P/E/G ratio of 5.54, the stock may not be seen as a good growth investment relative to its earnings growth, suggesting that the stock price may not increase significantly in the near term.
Insider transactions show that a significant insider sold 11,592 shares recently, which could raise concerns about the company's future prospects and insider confidence.
Despite a strong institutional ownership of 87.75%, high concentration of ownership can lead to volatility if large investors decide to sell their stakes.
The beta of 0.57 indicates lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.

CME Forecast - Frequently Asked Questions

: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $236.13, with a high forecast of $269.00 and a low forecast of $180.00.
: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" CME shares.
: According to analysts, CME Group's stock has a predicted downside of -5.12% based on their 12-month stock forecasts.
: Over the previous 90 days, CME Group's stock had 1 downgrade by analysts.
: CME Group has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Oppenheimer, Piper Sandler, and Royal Bank of Canada in the past 90 days.
: Analysts like CME Group less than other "finance" companies. The consensus rating for CME Group is Reduce while the average consensus rating for "finance" companies is Moderate Buy. Learn more on how CME compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:CME) was last updated on 2/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CME Group (CME) Stock Forecast & Price Target